Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Gesundheitswesen ; 85(7): 649-656, 2023 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-36328158

RESUMO

How can we improve the interoperability of medical guidelines and the implementation and measurement of outcomes in medical health care for cancer patients as well as for care providers? This is the aim of the working group "Quality and Cross-linking". The following publication gives an overview of the targets reached in the development of guidelines together with quality indicators and documentation in cancer registries.


Assuntos
Oncologia , Neoplasias , Humanos , Alemanha , Neoplasias/terapia , Sistema de Registros , Controle de Qualidade
2.
Nature ; 464(7291): 993-8, 2010 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-20393554

RESUMO

The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumours from 50 different cancer types and/or subtypes that are of clinical and societal importance across the globe. Systematic studies of more than 25,000 cancer genomes at the genomic, epigenomic and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies.


Assuntos
Genética Médica/organização & administração , Genoma Humano/genética , Genômica/organização & administração , Cooperação Internacional , Neoplasias/genética , Metilação de DNA , Análise Mutacional de DNA/tendências , Bases de Dados Genéticas , Genes Neoplásicos/genética , Genética Médica/tendências , Genômica/tendências , Humanos , Propriedade Intelectual , Mutação , Neoplasias/classificação , Neoplasias/patologia , Neoplasias/terapia
3.
J Cancer Res Clin Oncol ; 149(2): 913-919, 2023 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-36241862

RESUMO

PURPOSE: An increasing number of international studies demonstrate serious negative effects of the COVID-19 pandemic on the timely diagnosis of cancer and on cancer treatment. Our study aimed to quantitatively and qualitatively evaluate the capacities of German Comprehensive Cancer Centers (CCCs) in different areas of complex oncology care during the first 2 years of the COVID-19 pandemic. METHODS: Prospective panel survey over 23 rounds among 18 CCCs in Germany between March 2020 and June 2022. RESULTS: The COVID-19 pandemic substantially affected the oncological care system in Germany during the first 2 years. Persistent limitations of care in CCCs primarily affected follow-up (- 21%) and psycho-oncologic care (- 12%), but also tumor surgery (- 9%). Substantial limitations were also reported for all other areas of multidisciplinary oncological care. CONCLUSIONS: This study documents the limitations of oncological care during the COVID-19 pandemic and highlights the need to develop strategies to avoid similar limitations in the future.


Assuntos
COVID-19 , Neoplasias , Humanos , COVID-19/epidemiologia , SARS-CoV-2 , Pandemias , Estudos Prospectivos , Neoplasias/epidemiologia , Neoplasias/terapia
4.
Mol Oncol ; 14(8): 1589-1615, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32749074

RESUMO

A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.


Assuntos
Neoplasias/terapia , Sobreviventes de Câncer , Ensaios Clínicos como Assunto , Europa (Continente) , Humanos , Neoplasias/prevenção & controle , Neoplasias/psicologia , Neoplasias/reabilitação , Inovação Organizacional , Cuidados Paliativos , Participação do Paciente , Especialização , Pesquisa Translacional Biomédica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA